Table of Contents

1 Study Coverage

• 1.1 Doxorubicin Product
• 1.2 Market Segments
• 1.3 Key Manufacturers Covered
• 1.4 Market by Type
  • 1.4.1 Global Doxorubicin Market Size Growth Rate by Product
  • 1.4.2 Lyophilized Powder
  • 1.4.3 Doxorubicin Injection
• 1.5 Market by End User
  • 1.5.1 Global Doxorubicin Market Size Growth Rate by End User
  • 1.5.2 Ovarian
  • 1.5.3 Multiple Myeloma
  • 1.5.4 Kaposi Sarcoma
  • 1.5.5 Leukemia
  • 1.5.6 Bone Sarcoma
  • 1.5.7 Breast
  • 1.5.8 Gastric
  • 1.5.9 Liver
  • 1.5.10 Kidney
• 1.6 Study Objectives
• 1.7 Years Considered

2 Executive Summary

• 2.1 Global Doxorubicin Market Size
  • 2.1.1 Global Doxorubicin Revenue 2014-2025
  • 2.1.2 Global Doxorubicin Sales 2014-2025
• 2.2 Doxorubicin Growth Rate by Regions
  • 2.2.1 Global Doxorubicin Sales by Regions
  • 2.2.2 Global Doxorubicin Revenue by Regions

3 Breakdown Data by Manufacturers

• 3.1 Doxorubicin Sales by Manufacturers
  • 3.1.1 Doxorubicin Sales by Manufacturers
  • 3.1.2 Doxorubicin Sales Market Share by Manufacturers
  • 3.1.3 Global Doxorubicin Market Concentration Ratio (CR5 and HHI)
• 3.2 Doxorubicin Revenue by Manufacturers
  • 3.2.1 Doxorubicin Revenue by Manufacturers (2014-2019)
  • 3.2.2 Doxorubicin Revenue Share by Manufacturers (2014-2019)
• 3.3 Doxorubicin Price by Manufacturers
• 3.4 Doxorubicin Manufacturing Base Distribution, Product Types
  • 3.4.1 Doxorubicin Manufacturers Manufacturing Base Distribution, Headquarters
  • 3.4.2 Manufacturers Doxorubicin Product Type
  • 3.4.3 Date of International Manufacturers Enter into Doxorubicin Market
• 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product

• 4.1 Global Doxorubicin Sales by Product
• 4.2 Global Doxorubicin Revenue by Product
• 4.3 Doxorubicin Price by Product

5 Breakdown Data by End User

• 5.1 Overview
• 5.2 Global Doxorubicin Breakdown Data by End User

6 North America

• 6.1 North America Doxorubicin by Countries
  • 6.1.1 North America Doxorubicin Sales by Countries
  • 6.1.2 North America Doxorubicin Revenue by Countries
  • 6.1.3 United States
  • 6.1.4 Canada
  • 6.1.5 Mexico
• 6.2 North America Doxorubicin by Product
• 6.3 North America Doxorubicin by End User

7 Europe

• 7.1 Europe Doxorubicin by Countries
  • 7.1.1 Europe Doxorubicin Sales by Countries
  • 7.1.2 Europe Doxorubicin Revenue by Countries
  • 7.1.3 Germany
  • 7.1.4 France
  • 7.1.5 UK
  • 7.1.6 Italy
  • 7.1.7 Russia
• 7.2 Europe Doxorubicin by Product
• 7.3 Europe Doxorubicin by End User

8 Asia Pacific

• 8.1 Asia Pacific Doxorubicin by Countries
  • 8.1.1 Asia Pacific Doxorubicin Sales by Countries
  • 8.1.2 Asia Pacific Doxorubicin Revenue by Countries
  • 8.1.3 China
  • 8.1.4 Japan
  • 8.1.5 Korea
  • 8.1.6 India
  • 8.1.7 Australia
  • 8.1.8 Indonesia
  • 8.1.9 Malaysia
  • 8.1.10 Philippines
  • 8.1.11 Thailand
  • 8.1.12 Vietnam
  • 8.1.13 Singapore
• 8.2 Asia Pacific Doxorubicin by Product
• 8.3 Asia Pacific Doxorubicin by End User

9 Central & South America

• 9.1 Central & South America Doxorubicin by Countries
  • 9.1.1 Central & South America Doxorubicin Sales by Countries
  • 9.1.2 Central & South America Doxorubicin Revenue by Countries
  • 9.1.3 Brazil
• 9.2 Central & South America Doxorubicin by Product
• 9.3 Central & South America Doxorubicin by End User

10 Middle East and Africa

• 10.1 Middle East and Africa Doxorubicin by Countries
  • 10.1.1 Middle East and Africa Doxorubicin Sales by Countries
  • 10.1.2 Middle East and Africa Doxorubicin Revenue by Countries
  • 10.1.3 GCC Countries
  • 10.1.4 Turkey
  • 10.1.5 Egypt
  • 10.1.6 South Africa
• 10.2 Middle East and Africa Doxorubicin by Product
• 10.3 Middle East and Africa Doxorubicin by End User

11 Company Profiles

• 11.1 Sun Pharmaceuticals
  • 11.1.1 Sun Pharmaceuticals Company Details
  • 11.1.2 Company Business Overview
  • 11.1.3 Sun Pharmaceuticals Doxorubicin Sales, Revenue and Gross Margin (2014-2019)
  • 11.1.4 Sun Pharmaceuticals Doxorubicin Products Offered
  • 11.1.5 Sun Pharmaceuticals Recent Development
• 11.2 Pfizer
  • 11.2.1 Pfizer Company Details
  • 11.2.2 Company Business Overview
  • 11.2.3 Pfizer Doxorubicin Sales, Revenue and Gross Margin (2014-2019)
  • 11.2.4 Pfizer Doxorubicin Products Offered
  • 11.2.5 Pfizer Recent Development
• 11.3 Cipla
  • 11.3.1 Cipla Company Details
  • 11.3.2 Company Business Overview
  • 11.3.3 Cipla Doxorubicin Sales, Revenue and Gross Margin (2014-2019)
  • 11.3.4 Cipla Doxorubicin Products Offered
  • 11.3.5 Cipla Recent Development
• 11.4 Cadila Pharmaceuticals
  • 11.4.1 Cadila Pharmaceuticals Company Details
  • 11.4.2 Company Business Overview
  • 11.4.3 Cadila Pharmaceuticals Doxorubicin Sales, Revenue and Gross Margin (2014-2019)
  • 11.4.4 Cadila Pharmaceuticals Doxorubicin Products Offered
  • 11.4.5 Cadila Pharmaceuticals Recent Development
• 11.5 SRS Pharmaceuticals
  • 11.5.1 SRS Pharmaceuticals Company Details
  • 11.5.2 Company Business Overview
  • 11.5.3 SRS Pharmaceuticals Doxorubicin Sales, Revenue and Gross Margin (2014-2019)
  • 11.5.4 SRS Pharmaceuticals Doxorubicin Products Offered
  • 11.5.5 SRS Pharmaceuticals Recent Development

12 Future Forecast

• 12.1 Doxorubicin Market Forecast by Regions
  • 12.1.1 Global Doxorubicin Sales Forecast by Regions 2019-2025
  • 12.1.2 Global Doxorubicin Revenue Forecast by Regions 2019-2025
• 12.2 Doxorubicin Market Forecast by Product
  • 12.2.1 Global Doxorubicin Sales Forecast by Product 2019-2025
  • 12.2.2 Global Doxorubicin Revenue Forecast by Product 2019-2025
• 12.3 Doxorubicin Market Forecast by End User
• 12.4 North America Doxorubicin Forecast
• 12.5 Europe Doxorubicin Forecast
• 12.6 Asia Pacific Doxorubicin Forecast
• 12.7 Central & South America Doxorubicin Forecast
• 12.8 Middle East and Africa Doxorubicin Forecast

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

• 13.1 Market Opportunities and Drivers
• 13.2 Market Challenges
• 13.3 Market Risks/Restraints
• 13.4 Macroscopic Indicators

14 Value Chain and Sales Channels Analysis

• 14.1 Value Chain Analysis
• 14.2 Doxorubicin Customers
• 14.3 Sales Channels Analysis
  • 14.3.1 Sales Channels
  • 14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix

• 16.1 Research Methodology
  • 16.1.1 Methodology/Research Approach
  • 16.1.2 Data Source
• 16.2 Author Details

Doxorubicin is a kind of antitumor antibiotics, can inhibit the synthesis of RNA and DNA, RNA in the strongest inhibitory effect.
Doxorubicin has an effect on a wide variety of tumor, belongs to the cycle non-specific drug, have all sorts of growth cycle of tumor cells to kill.it's given by injection into a vein.
The global Doxorubicin market is valued at 910 million US$ in 2018 and will reach 1410 million US$ by the end of 2025, growing at a CAGR of 5.6% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Doxorubicin market based on company, product type, end user and key regions.

This report studies the global market size of Doxorubicin in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Doxorubicin in these regions.
This research report categorizes the global Doxorubicin market by top players/brands, region, type and end user. This report also studies the global Doxorubicin market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Sun Pharmaceuticals
Pfizer
Cipla
Cadila Pharmaceuticals
SRS Pharmaceuticals

Market size by Product
Lyophilized Powder
Doxorubicin Injection
Market size by End User
Ovarian
Multiple Myeloma
Kaposi Sarcoma
Leukemia
Bone Sarcoma
Breast
Gastric
Liver
Kidney

Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa

The study objectives of this report are:
To study and analyze the global Doxorubicin market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Doxorubicin market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Doxorubicin companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Doxorubicin submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Doxorubicin are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025

This report includes the estimation of market size for value (million US$) and volume (Kg). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Doxorubicin market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.